Investieren in die Zukunft von morgen.
Seite 84 von 229 Neuester Beitrag: 23.05.11 20:13 | ||||
| Eröffnet am: | 25.06.09 04:47 | von: brunneta | Anzahl Beiträge: | 6.709 |
| Neuester Beitrag: | 23.05.11 20:13 | von: buddikatze | Leser gesamt: | 469.606 |
| Forum: | Hot-Stocks | Leser heute: | 185 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 81 | 82 | 83 | | 85 | 86 | 87 | ... 229 > | ||||
geworfen wurden, gedacht sind.
Und ob noch mehr emittiert werden sollen. Kann leider kein englisch.
Optionen
| Boardmail an "raurunter" |
Wertpapier: Cord Blood America |
Genau solche Fragen soll und muss sich Matt sicher stellen können.
Der Thread im Link:Zukunftsaussicht erst ab Anfang Februar 2010....
http://forum.stocks.ch/forum/Kein_Kaufsignal-t394493
demnach wirst du im Febr. 2010 nur noch positiv über CBAI schreiben...(?)
MfG reanimatore
Habe vor hier zu investieren. Frage,wer kennt sich aus,hat Cord Blood vor kurzem ein R-Splitt gehabt?
Oder wird eventuell was geplannt.
Danke im voraus.
Optionen
| Boardmail an "raurunter" |
Wertpapier: Cord Blood America |
...bin ab MO wieder dabei -- ax
Date : 11/23/2009 @ 8:00AM
Source : PR Newswire
Stock : (CBAI)
http://ih.advfn.com/...pid=nmona&article=40472230&symbol=CBAI
LAS VEGAS, Nov. 23 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that an updated progress interview with CEO and co-founder Matthew Schissler is now available.
The entire interview is at: http://blip.tv/file/2875811 .
In the interview, Mr. Schissler updates progress at the Company's laboratory in Las Vegas, answers questions asked on the Company's "Facebook" fan page, and shows off the new facility for investors to view.
"My message is: 2010 will focus on top-line revenue growth including organic growth, acquisitions, and diversifying the revenue streams," Cord Blood America's CEO said.
About Cord Blood America
Cord Blood America (OTC:CBAI) (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC:CBAI) (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
CONTACT: Paul Knopick E & E Communications 949/707-5365
DATASOURCE: Cord Blood America, Inc.
CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,
, for Cord Blood America, Inc.
Web Site: http://www.cordblood-america.com/
Optionen
| Boardmail an "fuerza_hercuela" |
Wertpapier: Cord Blood America |
Hat jemand noch einen funktionierenden Link?
Oder vielmehr weiß jemand was genau hier besprochen wurde.
P.S. Meine Vision ist, dass irgendwann 1$ pro Aktie bezahlt wird
egal wann dies passieren wird, ich werde dabei sein.
Optionen
| Boardmail an "totopoff" |
Wertpapier: Cord Blood America |
Optionen
| Boardmail an "raurunter" |
Wertpapier: Cord Blood America |
rechts oben anklicken
http://www.cordblood-america.com/Information/corporate-overview-for-investors.html
und wenn der Kurs noch mal runter geht kauf ich alles was ich bekomme und in ein paar Jahren sprechen wir uns wieder.........mit ner Zigarre im Mund auf´m Golfplatz
frei übersetzt..das ist die Zukunft und die hat begonnen!!
Dr O'Neill sagte, "CBAI wird Bestandteile liefern, die in medizinischen Verfahren für die Nervenregeneration, Knorpel-Regeneration, und die Regeneration des Muskels und der anderen Gewebe zu verwenden sind. Wir arbeiten, um Schnur-Blut Amerika ein Zellentherapie-Dienstversorger zu machen, den wir glauben, ist, wo die Zukunft wohnt," erklärte Dr O'Neill. "Wir werden wie eine Zellapotheke werden."
Optionen
| Boardmail an "raurunter" |
Wertpapier: Cord Blood America |
Optionen
| Boardmail an "schilo-nrw" |
Wertpapier: Cord Blood America |
Just for INFO noch dies:
Science News Share Blog Cite Print Email BookmarkUmbilical Cord Blood Stem Cell Transplant May Help Lung, Heart Disorders
ScienceDaily (Nov. 23, 2009) — Two separate studies published in the current issue of Cell Transplantation -- have shown that transplanted human-derived umbilical cord blood (UCB) stem cells transplanted in an animal model had positive therapeutic effects on specific lung and heart disorders the animal models.
--------------------------------------------------
See Also:
Health & Medicine
•Stem Cells
•Lung Cancer
•Lung Disease
Plants & Animals
•Biology
•Developmental Biology
•Molecular Biology
Reference
•Stem cell treatments
•Embryonic stem cell
•Transplant rejection
•Adult stem cell
"Human UCB-derived MSCs (mesenchymal stem cells) have been successfully isolated, cultivated and been shown to differentiate into various cell types, such as osteoblasts, chondrocytes, adipocytes, stromal cells, skeletal cells, endothelial cells and neural cells and even lung-specific cells in vitro," said corresponding author of the first study, Dr. Won Soon Park from the Samsung Medical Center, Seoul, Korea. "It is not known, however, if human UCB-derived MSCs can differentiate into lung-specific cell types in vivo."
To find out, the researchers investigated the therapeutic benefits of transplanting human umbilical cord blood (UCB) mensenchymal stem cells (MSCs) into newborn laboratory rats with oxygen-deprived lung injury. They found that MSCs have a protective effect against hyperoxia-induced lung injury, likely due to anti-inflammatory effects. The researchers noted that their findings are expected to have important therapeutic potential for the currently untreatable hyperoxic neonatal lung disease, or bronchopulmonary dysplasia (BPD), in premature human infants. The easy availability of UCB is an associated benefit.
Dr. Park noted that the optimal route for transplantation had not previously been determined.
"An injured lung produces soluble factors that cause MSCs to proliferate and migrate toward an injured lung," he explained. "But it has been unclear if the local, intratracheal administration of MSCs is comparable to, or better than systemic transplantation."
The researchers found that the intratracheal, rather than the intraperitoneal transplantation of human UCB-derived MSCs, significantly attenuated the hyperoxia-induced lung injury, such as decreased alveolarization and fibrosis. Survival rate was not improved by the MSC transplants, however. Questions remain over whether the donor cells exert a therapeutic effect by inducing direct tissue repair and regeneration of damaged cells, said the researchers.
A research team in Germany evaluated the feasibility and efficacy of autologous (self-donated) umbilical cord blood mononuclear cell (UCMNC) transplantation on right ventricular (RV) function in a large animal model of chronic RV overload. Their study examined the potential therapeutic role of UCMNCs in treating one of the most common cyanotic congenital heart defects in the Tetralogy of Fallot (TOF), a group of congenital heart defects.
They found that the transplant enhanced diastolic properties, likely through blood vessel growth (angiogenesis). The authors noted that UCMNCs have already been shown to be therapeutic agents in patients suffering from major hematological disorders.
"Surgical repair is inevitable and aims to normalize pulmonary blood flow by correcting the abnormal anatomy of the right ventricular outflow tract, but no experimental approach has been conducted to study the potential of stem cell treatment in RV volume overload," said corresponding author Dr. Can Yerebakan of the University of Rostock, Rostock, Germany.
They concluded that UCMNC transplantation was "feasible and safe" and seemed to "positively influence the diastolic properties of the RV under chronic volume overload."
Three months post-transplantation into laboratory sheep, the researchers were able to observe an alteration in the RV function, which is one of the long-term determinants of morbidity and mortality after TOF correction.
"We observed significantly enhanced capillary formation in the cell group, which yielded the possible explanation of better diastolic function achieved by cell transplantation," said Dr. Yerebakan. "This finding indicates the potential importance of UCB for RV modeling after infundibulotomy."
"These two studies add to the plethora of potential uses for UBC, ranging from possible treatments for neurological disorders, such as stroke and Alzheimer's disease to Diabetes, and now the repair of damaged heart and lungs," commented Section Editor Dr. Julio Voltarelli, professor of clinical medicine and clinical immunology in the Head, Bone Marrow Transplantation Unit at the University Hospital (Hospital das Clínicas), University of São Paulo, Brazil
Das Potenzial von CBAI ist meiner Meinung nach schon enorm - auch wenn 1$ etc. etwas übertrieben ist ;-)
Glück auf!
Hier schon Google-Übersetzung aus der neuesten NEWS:
PicksThatMove.com kündigt Investment Stellungnahme zu LDK Solar Co Ltd, Coalcorp Mining Inc., Encore Renaissance Resources Corp, Starbucks Corp und Cord Blood America Inc.
Business Wire ReleasesPublished News: 11/23/09 12:26 PM EST
Veröffentlicht von:
PicksThatMove.com
Bewertung:
In Verbindung stehende Vorräte:
CBAICCJEZ
LDKSBUX
DIGGdel.icio.usTechnoratiNewsvine
PicksThatMove ist erfreut, den Investoren besondere Situation Bestände, die ein hohes Potenzial für die Preisentwicklung Wertschätzung haben. Diese Firmen haben interessante Geschäftsmodelle und sie müssen sich auf die Geschäftsentwicklung Ebene ausführen, um Wert für die Aktionäre zu bringen. Einige unserer Vergangenheit holt hatte über 200% gestiegen. Um einige unserer profilierten Bestände anzuzeigen, besuchen Sie bitte unsere Website unter www.picksthatmove.com.
2523 Anhänger, wenn hier jeder nur 500000 Aktien hält sind 1261500000 Aktien in festen Händen.
nur so am Rande